Dasantafil (Synonyms: SCH-446132)

Cat. No.: HY-106230A Purity: 98.35%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Dasantafil (SCH-446132) is a small molecule phosphodiesterase-5A (PDE5A) inhibitor used to in genitourinary disorders and study erectile dysfunction.

For research use only. We do not sell to patients.

Dasantafil Chemical Structure

CAS No. : 569351-91-3

Size	Price	Stock	Quantity
5 mg	USD 30	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 45	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms

PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

Biological Activity
Purity & Documentation
References
Customer Review

Description

Dasantafil (SCH-446132) is a small molecule phosphodiesterase-5A (PDE5A) inhibitor used to in genitourinary disorders and study erectile dysfunction^[1].

Molecular Weight

522.39

Formula

C₂₂H₂₈BrN₅O₅

CAS No.

569351-91-3

Appearance

Solid

Color

White to off-white

SMILES

OCCN(C(N(C1=O)CC)=O)C(N=C2N[C@H]3[C@@H](CCC3)O)=C1N2CC4=CC(Br)=C(C=C4)OC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (191.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9143 mL	9.5714 mL	19.1428 mL
5 mM	0.3829 mL	1.9143 mL	3.8286 mL
10 mM	0.1914 mL	0.9571 mL	1.9143 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.35%

Select Batch:

Data Sheet (275 KB) SDS (251 KB)

COA (255 KB) LCMS (84 KB)

Handling Instructions (2659 KB)

References

[1]. Galo M, et al. Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review. Pulm Circ. 2020 Jul-Sep; 10(3): 2045894020948780.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9143 mL	9.5714 mL	19.1428 mL	47.8570 mL
	5 mM	0.3829 mL	1.9143 mL	3.8286 mL	9.5714 mL
	10 mM	0.1914 mL	0.9571 mL	1.9143 mL	4.7857 mL
	15 mM	0.1276 mL	0.6381 mL	1.2762 mL	3.1905 mL
	20 mM	0.0957 mL	0.4786 mL	0.9571 mL	2.3928 mL
	25 mM	0.0766 mL	0.3829 mL	0.7657 mL	1.9143 mL
	30 mM	0.0638 mL	0.3190 mL	0.6381 mL	1.5952 mL
	40 mM	0.0479 mL	0.2393 mL	0.4786 mL	1.1964 mL
	50 mM	0.0383 mL	0.1914 mL	0.3829 mL	0.9571 mL
	60 mM	0.0319 mL	0.1595 mL	0.3190 mL	0.7976 mL
	80 mM	0.0239 mL	0.1196 mL	0.2393 mL	0.5982 mL
	100 mM	0.0191 mL	0.0957 mL	0.1914 mL	0.4786 mL

Dasantafil Related Classifications

Others

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Dasantafil569351-91-3SCH-446132SCH446132SCH 446132Phosphodiesterase (PDE)genitourinary disorderserectile dysfunctionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks